Who is sponsoring NCT04920318?

NCT04920318 is sponsored by University of Arizona.

What drugs are being tested in NCT04920318?

Interventions in NCT04920318: tDCS + language therapy, sham TDCS + language therapy.

What condition does NCT04920318 study?

NCT04920318 studies Primary Progressive Aphasia.

Is NCT04920318 still recruiting?

NCT04920318 is currently recruiting now. Last updated 29 November 2024.

Last reviewed 2024-11-29 · How we verify

NCT04920318: PPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhancing Language Function in Primary Progressive Aphasia

Recruiting now NA Last updated 29 November 2024

What this trial tests

NA trial testing tDCS + language therapy in Primary Progressive Aphasia in 20 participants. Currently enrolling.

Timeline

30 August 2021

Primary endpoint
30 December 2026

15 June 2027

Quick facts

Lead sponsor	University of Arizona
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	20
Start date	30 August 2021
Primary completion	30 December 2026
Estimated completion	15 June 2027
Sites	1 location across United States

Drugs / interventions tested

tDCS + language therapy
sham TDCS + language therapy

Conditions studied

Primary Progressive Aphasia — all drugs for Primary Progressive Aphasia →

Sponsor

University of Arizona

Who can join

Adults 45 to 80, any sex, with Primary Progressive Aphasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Non-pharmacological interventions for improving language and communication in people with primary progressive aphasia.
Roheger M, Riemann S, Brauer A, McGowan E, et al · · 2024 · cited 13× · PMID 38808659 · DOI 10.1002/14651858.cd015067.pub2

Verify or expand the search:

Other recruiting trials for Primary Progressive Aphasia

Currently open trials in the same condition.

NCT06191198 — Communication Bridge 3 Study · Phase 2 · recruiting
NCT06211374 — Communication Bridge Pilot Study · NA · active not recruiting
NCT05386394 — Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia · Phase 2 · recruiting
NCT05741853 — Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia · NA · recruiting
NCT05443633 — Enhancing Language Function in Aphasia · NA · recruiting

Other University of Arizona trials

Trials by the same sponsor.

NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04920318 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arizona
Last refreshed: 29 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04920318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing